Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05626855 · ClinicalTrials.gov registry record · Phase 3
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
A Phase 3 study of Spinal Muscular Atrophy and Neuromuscular Diseases, sponsored by Scholar Rock.
- Active
- Registry status
- Phase 3
- Development phase
- 238
- Enrollment target
- 20
- Study locations
NCT05626855 is a Phase 3 study of Spinal Muscular Atrophy and Neuromuscular Diseases that is active but no longer recruiting, run by Scholar Rock. The registered enrollment target is 238 participants, above the 98-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (143% higher). The trial reports 20 study locations across 18 states.
The verdict
NCT05626855, a Phase 3 study of Spinal Muscular Atrophy and Neuromuscular Diseases, is active but no longer recruiting, sponsored by Scholar Rock.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 238 participants
- Enrollment target
- 20
- Study locations
Study Summary
The ONYX study is an Open-Label, Multicenter, Extension study that will evaluate the long-term safety and efficacy of Apitegromab in Patients with Type 2 and Type 3 SMA who have completed TOPAZ or SAPPHIRE.
Conditions Studied
Interventions
- DRUG Apitegromab
Study Locations (20)
California
- UCSD Altman Clinical and Translational Research - La Jolla
- Children's Hospital Los Angeles - Los Angeles
- Stanford Neuroscience Health Center - Palo Alto
Arizona
- Phoenix Childrens Hospital - Phoenix
Colorado
- Children's Hospital Colorado - Aurora
Florida
- Nemours Biomedical Research - Orlando
Illinois
- Lurie Children's Hospital of Chicago - Chicago
Iowa
- University of Iowa - Iowa City
Kansas
- University of Kansas Medical Center - Fairway
Maryland
- Johns HopkinsHospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2023-04-17 |
| Est. Completion | 2029-05-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05626855
The ClinicalTrials.gov registry entry for NCT05626855 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 238 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 98-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (143% higher). The listed sponsor is Scholar Rock, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Spinal Muscular Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Apitegromab is the first listed.
NCT05626855 reports 20 study locations spanning 18 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT05626855 about?
NCT05626855 is a clinical study titled "Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab". The ONYX study is an Open-Label, Multicenter, Extension study that will evaluate the long-term safety and efficacy of Apitegromab in Patients with Type 2 and Type 3 SMA who have completed TOPAZ or SAPPHIRE.
What is the current status of trial NCT05626855?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 238 participants. The study started on 2023-04-17. Estimated completion is 2029-05-02.
What conditions does trial NCT05626855 study?
This clinical trial studies the following conditions: Spinal Muscular Atrophy, Neuromuscular Diseases, Muscular Atrophy, Spinal, Spinal Muscular Atrophy Type 3, Neuromuscular Manifestations.
What interventions are being tested in trial NCT05626855?
The interventions under investigation include: Apitegromab (DRUG).
Who is sponsoring clinical trial NCT05626855?
This trial is sponsored by Scholar Rock, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05626855 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Muscular Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
COMPLETED · Phase 3
-
Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA
RECRUITING
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RECRUITING · NA
-
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.